Skip to main content

Epoch Biosciences Licenses Hybridization Technology from Applied Biosystems

NEW YORK, June 25 – Epoch Biosciences has licensed technology from Applied Biosystems for SNP detection and gene expression assays, the company said Monday. 

The technology, for using non-cleavable fluorescent self-quenching probes in hybridization assays, will be incorporated into the company’s assays for measuring gene expression and detecting SNPs. The company plans to release the first version of the assays this summer, in the launch of Epoch’s first product for the commercial market.

Epoch, based in Bothell, Wash., currently licenses its genetic analysis technology to Applied Biosystems and Third Wave Technologies, who use the technology for their commercial SNP detection and gene expression products.

Last year the company acquired Synthetic Genetics, a San Diego-based manufacturer of modified oligonucleotides, for $3.1 milion in cash.

"We are pleased to provide our probe technology to Epoch Biosciences as they near the release of their Eclipse probe line," Michael Lucero, vice president of applications marketing and R&D at Applied Biosystems, said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.